Methyl analogues of the experimental Alzheimer drug phenserine: Synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action

Journal of Medicinal Chemistry

Volumn 44, Issue 24, 2001, Pages 4062-4071

  Yu, Q ^a   Holloway, H W ^a   Flippen Anderson, J L ^b   Hoffman, B ^c   Brossi, A ^d   Greig, N H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NAVAL RESEARCH LABORATORY   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; PHENSERINE; PHYSOSTIGMINE;

ALZHEIMER DISEASE; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; CARBAMATES; CHOLINESTERASE INHIBITORS; CRYSTALLOGRAPHY, X-RAY; ERYTHROCYTES; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHYSOSTIGMINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035935699     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010080x     Document Type: Article

References (45)

1. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
2. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
3. The cholinergic hypothesis of geriatric memory dysfunction
4. Cholinesterase inhibitors do more than inhibit cholinesterase
5. Cholinesterase inhibitors: From the Calabar bean to Alzheimer therapy
6. Choline and cholinergic neurons
7. Intravenous nicotine in Alzheimer's disease: A pilot study
8. Effects of muscarinic and adrenergic agonism on auditory P300 in the macaque
9. Phenserine and ring C hetero-analogues: Drug candidates for treatment of Alzheimer's disease
10. Cholinesterase inhibitors as therapy in Alzheimer's disease: Benefit to risk considerations in clinical application
11. Structure-activity relationships of the reversible anticholinesterase agent
12. Reactions of cholinesterase with substrates, inhibitors and reactivators
13. Acetylcholinesterase: Enyme structure, reaction dynamics and virtual transition states
14. Amplification of butyrylcholinesterase and acetylcholinesterase genes in normal and tumor tissues: Putative relationship to organophosphorous poisoning
15. The cholinesterases
16. Atomic structure of acetylcholinesterase from Torpedo Californica: A prototypic acetylcholine-binding protein
17. The cholinesterases: From genes to proteins
18. Structure-activity relationship in the binding of reversible inhibitors in the active-site gorge of acetylcholinesterase
19. Rational design of cholinesterase inhibitors
20. Structural studies of acetylcholinesterase
21. Mechanism of action of cholinesterase inhibitors
22. Invited review. Phenserine, a novel anticholinesterase related to physostigmine: Total synthesis and biological properties
23. Selective inhibition of acetyl- and butyrylcholinesterases by phenylcarbamates of(-)-eseroline, (-)-(N1)-noreseroline and physovenol
24. Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues
25. Syntheses and anticholinesterase activities of (3aS)-N(1), N(8)-bisnor-phenserine(3aS)-N(1), N(8)-bisnorphysostigmine their antipodal isomers, and other potential metabolites of phenserine
26. Syntheses and biological evaluation of ring-C opened analogues of the cholinesterase inhibitors physostigmine, phenserine and cymserine
27. The synthesis of novel selective inhibitors of butyrylcholinesterase based on phenserine for Alzheimer's disease
28. Carbamate analogues of (-)-physostigmine: In vitro inhibition of acetyl- and butlcholinesterases
29. (3aS)-eseroline carbamate (II), a potent cholinesterase inhibitor and close analogue of physostigmine: Reanalysis
30. Dissection of the human acetylcholinesterase active center determinants of substrate specificity
31. Amino acid residues controlling acetylcholinesterase and butyrylesterase specificity
32. Conversion of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis
33. Human acetylcholinesterase inhibition kinetics of the experimental Alzheimer therapeutic, tolserine
34. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: Phenserine
35. Noncometitive inhibition of acetylcholine by eserine
36. Comparative inhibitory effect of various physostigmine analogues against acetyl- and butyrylcholinesterases